Download - Nerve Agents
1LPC/CBRN 24 Jan 06 C191W047/1
Nerve AgentsNerve Agents
2LPC/CBRN 24 Jan 06 C191W047/1
IntroductionIntroduction
Chemical weapons Chemical weapons have been around for have been around for decades.decades.
Nerve agents among Nerve agents among the most deadly.the most deadly.
Manufactured by Manufactured by simple techniques.simple techniques.
Raw materials are Raw materials are inexpensive and inexpensive and readily available.readily available.
3LPC/CBRN 24 Jan 06 C191W047/1
Overview of Nerve AgentsOverview of Nerve Agents
Developed in Germany.Developed in Germany. Only known Only known
battlefield use is in battlefield use is in the Iran-Iraq the Iran-Iraq conflict.conflict.
Many countries Many countries have the technology have the technology to develop nerve to develop nerve agents.agents.
Terrorist attacks in Japan.Terrorist attacks in Japan.
4LPC/CBRN 24 Jan 06 C191W047/1
Overview of Nerve AgentsOverview of Nerve Agents
Hazards in liquid and Hazards in liquid and vapor state.vapor state.
Dispersed from missiles, Dispersed from missiles, bombs, spray tanks, land bombs, spray tanks, land mines, and other mines, and other munitions.munitions.
5LPC/CBRN 24 Jan 06 C191W047/1
Overview of Nerve AgentsOverview of Nerve Agents
Acetylcholine (ACh) is a Acetylcholine (ACh) is a neurotransmitter in the neurotransmitter in the nervous system.nervous system.
Acetylcholinesterase Acetylcholinesterase (AChE) (an enzyme) (AChE) (an enzyme) stops the action of Ach.stops the action of Ach.
Nerve agents bind to Nerve agents bind to AChE.AChE.
ACh builds up and ACh builds up and continues to act.continues to act.
6LPC/CBRN 24 Jan 06 C191W047/1
Normal ACh TransmissionNormal ACh Transmission Nerve to Nerve Nerve to Nerve
ACh
7LPC/CBRN 24 Jan 06 C191W047/1
Normal ACh TransmissionNormal ACh Transmission Nerve to Nerve Nerve to Nerve
ACh
8LPC/CBRN 24 Jan 06 C191W047/1
Normal ACh TransmissionNormal ACh Transmission Nerve to Nerve Nerve to Nerve
ACh
9LPC/CBRN 24 Jan 06 C191W047/1
Normal ACh TransmissionNormal ACh Transmission Nerve to Skeletal Muscle-Stimulation Nerve to Skeletal Muscle-Stimulation
10
LPC/CBRN 24 Jan 06 C191W047/1
Normal ACh TransmissionNormal ACh TransmissionNerve to Smooth Muscle-StimulationNerve to Smooth Muscle-Stimulation
11
LPC/CBRN 24 Jan 06 C191W047/1
Normal ACh TransmissionNormal ACh Transmission Nerve to Glands-Normal secretions Nerve to Glands-Normal secretions
12
LPC/CBRN 24 Jan 06 C191W047/1
Impulse Termination: Impulse Termination: The Role of AChEThe Role of AChE
ACh
AChE
13
LPC/CBRN 24 Jan 06 C191W047/1
Exposure to Nerve AgentExposure to Nerve Agent
ACh
AChE
14
LPC/CBRN 24 Jan 06 C191W047/1
Exposure to Nerve Agent-Binds Exposure to Nerve Agent-Binds AChE- causing excessive AChE- causing excessive
stimulationstimulation
ACh
AChE
15
LPC/CBRN 24 Jan 06 C191W047/1
Nerve Agents Effects: Nerve Agents Effects: Skeletal Muscle-Over stimulationSkeletal Muscle-Over stimulation
ACh
AChE
16
LPC/CBRN 24 Jan 06 C191W047/1
Impulse Termination: Impulse Termination: The Role of AChE-The Role of AChE-Stops stimulationStops stimulation
ACh
AChE
17
LPC/CBRN 24 Jan 06 C191W047/1
Nerve Agents Effects:Nerve Agents Effects: Smooth and Cardiac Muscle Smooth and Cardiac Muscle
ACh
AChE
18
LPC/CBRN 24 Jan 06 C191W047/1
Nerve Agents Effects on Glands- Nerve Agents Effects on Glands- Increased SecretionsIncreased Secretions
ACh
AChE
19
LPC/CBRN 24 Jan 06 C191W047/1
Nerve Agent CharacteristicsNerve Agent Characteristics
Liquid unless exposed Liquid unless exposed to extreme heat or cold.to extreme heat or cold.
Volatility.Volatility. Colorless to light Colorless to light
brown.brown. Odorless.Odorless. Routes of entry.Routes of entry.
20
LPC/CBRN 24 Jan 06 C191W047/1
Levels of Exposure and Levels of Exposure and Clinical EffectsClinical Effects
Depends of dosage Depends of dosage and route of exposure.and route of exposure.
Vapor effects are Vapor effects are different than liquid different than liquid effects.effects.
21
LPC/CBRN 24 Jan 06 C191W047/1
Level of Exposure - MildLevel of Exposure - Mild
VaporVapor::
– Causes effects in eyes, Causes effects in eyes,
nose and lungs- local nose and lungs- local
and/or systemic effectand/or systemic effect LiquidLiquid::
– Systemic Systemic
gastrointestinal effectgastrointestinal effect
22
LPC/CBRN 24 Jan 06 C191W047/1
Level of Exposure - MildLevel of Exposure - Mild
Rhinorrhea - may be Rhinorrhea - may be
the first sign.the first sign. Frontal headache/eye Frontal headache/eye
pain.pain. Difficulty in seeing.Difficulty in seeing. Tightness in chest.Tightness in chest.
23
LPC/CBRN 24 Jan 06 C191W047/1
Level of Exposure - MildLevel of Exposure - Mild
Difficulty breathing.Difficulty breathing. Drooling.Drooling. Localized sweating.Localized sweating. Muscle twitching.Muscle twitching.
24
LPC/CBRN 24 Jan 06 C191W047/1
Level of Exposure - SevereLevel of Exposure - Severe The signs and symptoms of mild nerve The signs and symptoms of mild nerve
agent exposure may occur plus:agent exposure may occur plus: Nausea, vomiting, diarrheaNausea, vomiting, diarrhea Severe muscle twitchingSevere muscle twitching SeizuresSeizures Loss of bladder and bowel controlLoss of bladder and bowel control Confused behavior, followed by LOCConfused behavior, followed by LOC Respiratory failure > deathRespiratory failure > death
25
LPC/CBRN 24 Jan 06 C191W047/1
Time Interval of EffectsTime Interval of Effects VaporVapor: seconds to : seconds to
minutes. No delay minutes. No delay period.period.
Liquid: delay in Liquid: delay in symptoms 1-30 symptoms 1-30 minutes. Small liquid minutes. Small liquid exposure - symptoms exposure - symptoms up to 18 hours.up to 18 hours.
26
LPC/CBRN 24 Jan 06 C191W047/1
Treatment Steps: Self-AidTreatment Steps: Self-Aid Protect yourself - put on your protective mask.Protect yourself - put on your protective mask. Give the alarm.Give the alarm. Perform a hasty Perform a hasty
self-evaluation.self-evaluation. Administer antidote if Administer antidote if
signs and symptoms signs and symptoms are noted: are noted:
27
LPC/CBRN 24 Jan 06 C191W047/1
Treatment Steps: Self-AidTreatment Steps: Self-Aid Use one MARK I Nerve Agent Antidote Kit Use one MARK I Nerve Agent Antidote Kit
(NAAK):(NAAK):
Use one Antidote Treatment, Nerve Agent Use one Antidote Treatment, Nerve Agent Auto-injector (ATNAA): Auto-injector (ATNAA):
28
LPC/CBRN 24 Jan 06 C191W047/1
Treatment Steps: Self-AidTreatment Steps: Self-Aid
Never administer more than one NAAK Never administer more than one NAAK or ATNAA to yourself.or ATNAA to yourself.
If you needed more than one NAAK/ If you needed more than one NAAK/ ATNAA, you would be too incapacitated ATNAA, you would be too incapacitated to know it.to know it.
29
LPC/CBRN 24 Jan 06 C191W047/1
Treatment Steps: Self-AidTreatment Steps: Self-Aid
Decontaminate skin if Decontaminate skin if necessary.necessary.
Put on protective clothing Put on protective clothing (MOPP level 4).(MOPP level 4).
Seek buddy-aid or Seek buddy-aid or medical care.medical care.
JSLISTJSLIST
30
LPC/CBRN 24 Jan 06 C191W047/1
Mark I NAAKMark I NAAK Includes:Includes:
– Atropine 2mgAtropine 2mg - blocks effects of acetylcholine - blocks effects of acetylcholine and produces symptom relief.and produces symptom relief.
– 2-PAM-Cl 600 mg2-PAM-Cl 600 mg - blocks transmission of - blocks transmission of nerve agent.nerve agent.
31
LPC/CBRN 24 Jan 06 C191W047/1
ATNAAATNAA Includes:Includes:
– Atropine 2.1 mgAtropine 2.1 mg..– 2-PAM-Cl 600 mg2-PAM-Cl 600 mg..
32
LPC/CBRN 24 Jan 06 C191W047/1
Treatment Steps: Buddy-AidTreatment Steps: Buddy-Aid
Protect yourself; then:Protect yourself; then:– Mask the casualtyMask the casualty– Check casualty and surrounding area for Check casualty and surrounding area for
expended auto-injectorsexpended auto-injectors– Administer total of 3 MARK I NAAK/ATNAA; Administer total of 3 MARK I NAAK/ATNAA;
use the casualties’ sets.use the casualties’ sets.
33
LPC/CBRN 24 Jan 06 C191W047/1
Treatment Steps: Buddy-AidTreatment Steps: Buddy-Aid Protect yourself (cont’d):Protect yourself (cont’d):
– Administer 1 Convulsant Administer 1 Convulsant Antidote for Nerve Agent Antidote for Nerve Agent (CANA) injector (CANA) injector
– Decontaminate the Decontaminate the casualtycasualty
– Assess effectiveness of Assess effectiveness of treatment (atropinization treatment (atropinization and cessation of and cessation of convulsions)convulsions)
34
LPC/CBRN 24 Jan 06 C191W047/1
Treatment Steps: Buddy-AidTreatment Steps: Buddy-Aid
Additional atropine can be given at Additional atropine can be given at 15 minute 15 minute intervalsintervals until signs of nerve agent poisoning until signs of nerve agent poisoning decrease:decrease:– Heart rate is above 90 beats per minuteHeart rate is above 90 beats per minute– Bronchial secretions are reducedBronchial secretions are reduced– Salivation is reducedSalivation is reduced
35
LPC/CBRN 24 Jan 06 C191W047/1
Treatment Steps: Buddy-AidTreatment Steps: Buddy-Aid
Additional CANA, up to a total of 3, can be Additional CANA, up to a total of 3, can be given at given at 5 to 10 minute intervals5 to 10 minute intervals if convulsions if convulsions persistpersist
36
LPC/CBRN 24 Jan 06 C191W047/1
CANA InjectorCANA Injector
Contains diazepam (anti-Contains diazepam (anti-seizure medication).seizure medication).
Given to all casualties Given to all casualties requiring 3 MARK I sets.requiring 3 MARK I sets.
Soldier medic may carry Soldier medic may carry extra CANA injectors and extra CANA injectors and may give additional may give additional CANA injectors in a CANA injectors in a seizing casualty.seizing casualty.
37
LPC/CBRN 24 Jan 06 C191W047/1
Treatment Steps: Buddy-AidTreatment Steps: Buddy-Aid
Secure used injectors to the Secure used injectors to the casualty’s upper left pocket casualty’s upper left pocket flap of the BDO; flap of the BDO; left pocket on the sleeve of left pocket on the sleeve of the JSLIST. the JSLIST.
Record all treatment given Record all treatment given on the casualty’s FMC. on the casualty’s FMC.
Evacuate and provide Evacuate and provide assisted ventilations, if assisted ventilations, if necessary.necessary.
38
LPC/CBRN 24 Jan 06 C191W047/1
Side Effects of AtropineSide Effects of Atropine
MildMild: dry mouth, skin : dry mouth, skin flushing, drowsiness, flushing, drowsiness, decreased combat decreased combat performance.performance.
SevereSevere: drowsiness, : drowsiness, fatigue, visual blurring, fatigue, visual blurring, increased heat injury increased heat injury risk.risk.
39
LPC/CBRN 24 Jan 06 C191W047/1
Medication Side EffectsMedication Side Effects
2-PAM-Cl2-PAM-Cl::Mild visual changesMild visual changes
CANACANA::
Decreased combat Decreased combat performanceperformance
40
LPC/CBRN 24 Jan 06 C191W047/1
Nerve Agent PretreatmentNerve Agent Pretreatment
1990 (Gulf War I), US 1990 (Gulf War I), US military fields military fields pyridostigmine bromide pyridostigmine bromide (NAPP) as a pretreatment (NAPP) as a pretreatment for nerve agent exposure.for nerve agent exposure.
NOT an antidote - not NOT an antidote - not taken taken afterafter exposure. exposure.
Mild side effects.Mild side effects.
41
LPC/CBRN 24 Jan 06 C191W047/1
Nerve Agent PretreatmentNerve Agent Pretreatment
Medication to be Medication to be taken at least taken at least 8 hours 8 hours prior to exposureprior to exposure..
Service members Service members issued one NAPP in issued one NAPP in high risk areas.high risk areas.
Chain of command Chain of command issues orders to start issues orders to start the NAPP.the NAPP.
42
LPC/CBRN 24 Jan 06 C191W047/1
SummarySummary
Nerve Agent Nerve Agent
CharacteristicsCharacteristics
Signs and Symptoms Signs and Symptoms
of Nerve Agent of Nerve Agent
ExposureExposure
Treatment StepsTreatment Steps
Nerve Agent Nerve Agent
PretreatmentPretreatment
43
LPC/CBRN 24 Jan 06 C191W047/1
Questions?Questions?